Duloxetine hydrochloride
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Posttraumatic Stress Disorders
Conditions
Posttraumatic Stress Disorders
Trial Timeline
Dec 1, 2005 → Jun 1, 2008
NCT ID
NCT00583193About Duloxetine hydrochloride
Duloxetine hydrochloride is a phase 3 stage product being developed by Eli Lilly for Posttraumatic Stress Disorders. The current trial status is unknown. This product is registered under clinical trial identifier NCT00583193. Target conditions include Posttraumatic Stress Disorders.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00071708 | Pre-clinical | Completed |
| NCT00960986 | Approved | Completed |
| NCT00437125 | Approved | Completed |
| NCT00266643 | Approved | Completed |
| NCT00583193 | Phase 3 | UNKNOWN |
| NCT00191594 | Phase 3 | Completed |
| NCT00191061 | Approved | Completed |
| NCT00479726 | Approved | Completed |
| NCT00036309 | Phase 3 | Completed |
| NCT00036335 | Phase 3 | Completed |
Competing Products
8 competing products in Posttraumatic Stress Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Adjunctive asenapine | Merck | Approved | 85 |
| sertraline (Zoloft) | Pfizer | Pre-clinical | 22 |
| Ziprasidone | Pfizer | Approved | 84 |
| Methylphenidate Hydrochloride 20 mg + Placebo Capsule + Galantamine 12 mg | Brain Biotech | Phase 2 | 44 |
| High THC/Low CBD Cannabis + High THC/High CBD Cannabis + Low THC/Low CBD Cannabis | Tilray | Phase 2 | 47 |
| Riluzole | Brain Biotech | Phase 1 | 25 |